Sagimet Biosciences (NASDAQ: SGMT) Progresses Denifanstat in Key Phase 3 Acne Trial
Sagimet Biosciences is advancing denifanstat, an oral treatment for moderate to severe acne, into a crucial U.S. Phase 3 clinical trial. Positive Phase 3 results from its license partner in China suggest potential efficacy, raising expectations for the ongoing U.S. study. With an estimated 10…